Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland
| العنوان: | Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland |
|---|---|
| المؤلفون: | Muireann Ni Chroinin, Barry Linnane, Noel G. McElvaney, Laura Kirwan, Shijun Zhou, M. Harrington, Cedric Gunaratnam, Michael O’Mahony, Brian Casserly, Charles G. Gallagher, David Mullane, G. Fletcher, Paul McNally, Paulina Jeleniewska, Abaigeal D. Jackson, Edward F. McKone, Barry J. Plant, Peter Greally, M. Herzig |
| المصدر: | Annals of the American Thoracic Society. 16:209-216 |
| بيانات النشر: | American Thoracic Society, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Adult, Genetic Markers, Male, Pulmonary and Respiratory Medicine, Pediatrics, medicine.medical_specialty, Adolescent, Cystic Fibrosis, Respiratory System Agents, Cystic Fibrosis Transmembrane Conductance Regulator, Quinolones, Aminophenols, Cystic fibrosis, Body Mass Index, Ivacaftor, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Forced Expiratory Volume, medicine, Humans, Longitudinal Studies, Registries, 030212 general & internal medicine, Child, Lung, business.industry, Real world outcomes, Middle Aged, medicine.disease, Anti-Bacterial Agents, Hospitalization, Treatment Outcome, 030228 respiratory system, Mutation, Female, Registry data, business, Ireland, Cohort study, Cftr modulator, medicine.drug |
| الوصف: | Patient registries have the potential to collect and analyze high-quality postauthorization data on new medicines.We used cystic fibrosis (CF) registry data to assess outcomes after the initiation of ivacaftor, a CF transmembrane conductance regulator (CFTR) potentiator approved for the treatment of CF with a defective gating CFTR mutation.Longitudinal trends were examined using mixed-effects regression analysis in 80 ivacaftor-treated patients with CF aged 6 to 56 years registered with the CF Registry of Ireland with at least 36 months of before and after commencement data. The effects of ivacaftor treatment on forced expiratory volume in 1 second (FEVIn the 36 months after ivacaftor initiation, FEVIn this study of real-world CF registry data, clinical outcomes improved and healthcare resource utilization decreased after commencing ivacaftor. |
| تدمد: | 2325-6621 2329-6933 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f6205b5662e7a1bc61df2781d429c9Test https://doi.org/10.1513/annalsats.201802-149ocTest |
| رقم الانضمام: | edsair.doi.dedup.....61f6205b5662e7a1bc61df2781d429c9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23256621 23296933 |
|---|